DBS signs exclusive license agreement with JLB

Decas Botanical Synergies, LLC. (DBS) today announced that it has signed an Exclusive License Agreement with a purchase option with JLB, Inc. developer and owner of broad-based patents covering cranberry and other vaccinium species. The patents include:

“Signing an exclusive license and purchase option for these patents is an important milestone for DBS”

United States Patents:

• 5,474,774 - Adhesion Inhibiting Composition
• 5,525,341 - Partially Purified Cranberry Anti-Adhesion Activity
• 5,646,178 - Cranberry Extract and Biologically Active Compounds Derived Therefrom
• 5,650,432 - Method of Treating or Preventing Non-Viral Infection

Australian Patents:

• 703158 - Method of Treating or Preventing Non-viral Microbial Infection
• 708657 - Adhesion Inhibiting Composition

United Kingdom Patent:

• 0752871 -Adhesion Inhibiting Vaccinium Extract

Additionally, DBS's licensing rights include a non-exclusive license with sublicensing rights to:

United States Patents:

• 6,608,102 and 6,720,353 - Plant Proanthocyanidin Extract Effective at Inhibition Adherence of Bacteria with P-Type Fimbriae to Surfaces

Copies of these patents may be accessed at http://www.decasbotanical.com/news&events.htm

Cranberry's Unique Health Benefits

There is a growing body of science that demonstrates that the cranberry possesses a unique combination of phytonutrients that help promote and maintain health, especially in the urinary tract. Urinary tract infections (UTIs) affect over 11 million women in the U.S. annually, and 25% of these recurrently, with a total annual cost approaching $2 billion. Research published in peer-reviewed, scientific journals has established that cranberries contain proanthocyanidins (PACs) with an unusual A-type linkage. These compounds are considered responsible for helping to protect against UTIs due to their anti-adhesion properties of pathogenic E. coli to uroepithelial cells and tissues. Additionally, this same bacterial anti-adhesion effect has been found elsewhere in the body against certain other bacteria, including those responsible for periodontal disease and H. pylori, the leading cause of stomach ulcers - a major risk factor for stomach cancer.

"Signing an exclusive license and purchase option for these patents is an important milestone for DBS," said Doug Klaiber, DBS CEO. "Given the broad coverage of these significant and fundamental patents, we now have the ability to protect our research investment, increase market share and defend our global leadership position in the rapidly growing cranberry nutraceutical market. It is our intention to leverage the intellectual property via the introduction of new innovative products and through strategic partnerships and supply agreements."